Nuvo is developing a hybrid hardware/software system, the INVU platform, that provides remote access to medical-grade data to all key participants in the pregnancy care ecosystem. Last week the company filed with the SEC to raise up to $50M in an initial public offering.
Nuvo’s INVU platform combines proprietary hardware for data collection, innovative cloud-based software for computational power and AI tools to optimize the pregnancy care experience on a global scale. INVU received a 510(k) clearance from the U.S. FDA for maternal and fetal heart rate monitoring in 2020 and a supplemental clearance for remote monitoring of uterine activity in May of 2021. Company leadership is comprised of dedicated data engineers, experienced medical and business professionals, software designers and proud parents who embrace a collective mission to give every life a better beginning.